The synthesis of compound 1 was accomplished starting from 4-(2-methoxyethyl)phenol in two steps via KOH-mediated substitution with epichlorohydrin and then H2SO4 catalyzed hydrolysis of the formed epoxide.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Safety of a drug molecule is dependent on various impurities formed during chemical process which may cause drug product instability, decreased product performance, loss in potency, and/or formation of potentially genotoxic impurities.
📊
Key Findings & Data:Therefore, it is essential to identify and quantify the impurities generated during the drug development stage.
💡
Conclusion & Impact:The synthesis of compound 1 was accomplished starting from 4-(2-methoxyethyl)phenol in two steps via KOH-mediated substitution with epichlorohydrin and then H2SO4 catalyzed hydrolysis of the formed epoxide.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
Safety of a drug molecule is dependent on various impurities formed during chemical process which may cause drug product instability, decreased product performance, loss in potency, and/or formation of potentially genotoxic impurities. Therefore, it is essential to identify and quantify the impurities generated during the drug development stage. Herein, we describe the synthesis and characterization of metoprolol EP Impurity D, 3-[4-(2- methoxyethyl)phenoxy]propane-1,2-diol (1), reported in European Pharmacopeia. The synthesis of compound 1 was accomplished starting from 4-(2-methoxyethyl)phenol in two steps via KOH-mediated substitution with epichlorohydrin and then H2SO4 catalyzed hydrolysis of the formed epoxide.
Saddique, F.A; Zahoor, A.F; Yousaf, M.; Irfan, M.; Ahmad, M.;Mansha, A.; Khan, Z.A.; Naqvi, S.A.R. Synthetic approaches towards the synthesis of beta-blockers (betaxolol, metoprolol, sotalol, and timolol). Turk. J. Chem. 2016, 40, 193-224
Hoffman, B.B. In Basic and Clinical Pharmacology; Katzung, B. G., Ed., 7th ed. Appleton-Lange: Stamford, CT, USA, 1998, 136-151
Reddy, R.B;, More, K.R, Gupta, L.; Jha, M.S.; Magar, L. Identification, synthesis, isolation and characterization of new impurity in metoprolol tartarate tablets. J. Pharm. Biomed. Anal., 2016, 117, 104– 108
Ye, Q.; Huang, Y.; Rusowicz, A.; Palaniswamy, V.A.; Raglino, T.V. Understanding and controlling the formation of an impurity during the development of muraglitazar, a PPAR dual agonist. Org. Process. Res. Dev. 2010, 14, 238–224
Kadivara, M.H.; Sinha, P.K.; Kushway, D.; Jana, P.; Sharma, H.; Bapodra, A. Study of impurity carryover and impurity profile in Febuxostat drug substance by LC–MS/MS technique. J. Pharm. Biomed. Anal., 2011, 56, 749–757
Gorog, S. New safe medicines faster: the role of analytical chemistry. Trends Anal. Chem. 2003, 22, 407- 415
Bartos, D; Gorog, S. Recent advances in the impurity profiling of drugs. Curr. Pharm. Anal. 2008, 4, 215- 230
Internation Conference on Harmonization (ICH) Guidelines, Q3A (R2): Impurities in New Drug Substances, March, 2020. Accessed 20 September 2020 [9] Internation Conference on Harmonization (ICH) Guidelines, Q3B (R2): Impurities in New Drug Products, March, 2020. Accessed 20 September 2020 [10] Internation Conference on Harmonization (ICH) Guidelines, Q3C (R8): Impurities guidelines for residual solvents. March, 2020. [Accessed 20 September 2020]
Pramanik, C; Bhumkar, R.; Karhade, G.; Khairnar, P.; Primaty, N.K.; Gurjar, M.K. Efficient synthesis of impurity-C of antimigraine agent rizatriptan benzoate. Org. Process Res. Dev. 2012, 16, 507−511
Cohnen, E. Substituted phenoxyalkanolamines and phenoxyalkanolcycloalkylamines, their pharmaceutical compositions and their intermediates x Eur. Pat. Appl. 82461, 29 Jun 1983
Gurjar, M K; Joshi, V S; Sastry, B S; Rama Rao, A V. A new route to (+) Metoprolol. Synth. Commun. 1990, 20, 3489-3496
Cave, G W V; Raston, C L. Scott, J. Recent advances in solventless organic reactions: towards benign synthesis with remarkable versatility. Chem. Commun. 2001, 2159-2169
Bose, D S; Fatima, L. Mereyala, H.B. Green chemistry approaches to the synthe